Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelika Michel

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Helicobacter|July 25, 2017
Antibody reactivity against Helicobacter pylori proteins in a sample of the Spanish adult population in 2008-2013Nerea Fernández-de-Larrea, Angelika Michel, Beatriz Romero, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|November 30, 2018
Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factorsIrene Lorenzo, Nerea Fernández-de-Larrea, Angelika Michel, et al.
Frontiers in Microbiology|June 15, 2017
<i>Helicobacter pylori</i> Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in SpainNerea Fernández de Larrea-Baz, Angelika Michel, Beatriz Romero, et al.
Papillomavirus Research (Amsterdam, Netherlands)|March 27, 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in IndiaNeerja Bhatla, Bhagwan M Nene, Smita Joshi, et al.
International Journal of Cancer|January 30, 2018
Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancerJulia Butt, Mazda Jenab, Martina Willhauck-Fleckenstein, et al.
Papillomavirus Research (Amsterdam, Netherlands)|February 4, 2019
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort studyPartha Basu, Richard Muwonge, Neerja Bhatla, et al.
The Lancet. Oncology|December 15, 2015
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyRengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 28, 2015
Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled AnalysisKrystle A Lang Kuhs, Devasena Anantharaman, Tim Waterboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition studyAimée R Kreimer, Paul Brennan, Krystle A Lang Kuhs, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Helicobacter|July 25, 2017
Antibody reactivity against Helicobacter pylori proteins in a sample of the Spanish adult population in 2008-2013Nerea Fernández-de-Larrea, Angelika Michel, Beatriz Romero, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|November 30, 2018
Helicobacter pylori seroprevalence in Spain: influence of adult and childhood sociodemographic factorsIrene Lorenzo, Nerea Fernández-de-Larrea, Angelika Michel, et al.
Frontiers in Microbiology|June 15, 2017
<i>Helicobacter pylori</i> Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in SpainNerea Fernández de Larrea-Baz, Angelika Michel, Beatriz Romero, et al.
Papillomavirus Research (Amsterdam, Netherlands)|March 27, 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in IndiaNeerja Bhatla, Bhagwan M Nene, Smita Joshi, et al.
International Journal of Cancer|January 30, 2018
Prospective evaluation of antibody response to Streptococcus gallolyticus and risk of colorectal cancerJulia Butt, Mazda Jenab, Martina Willhauck-Fleckenstein, et al.
Papillomavirus Research (Amsterdam, Netherlands)|February 4, 2019
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort studyPartha Basu, Richard Muwonge, Neerja Bhatla, et al.
The Lancet. Oncology|December 15, 2015
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyRengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 28, 2015
Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled AnalysisKrystle A Lang Kuhs, Devasena Anantharaman, Tim Waterboer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition studyAimée R Kreimer, Paul Brennan, Krystle A Lang Kuhs, et al.
Pageof 8